HK Stock MarketDetailed Quotes

02315 BIOCYTOGEN-B

Watchlist
  • 6.220
  • +0.220+3.67%
Market Closed Aug 15 16:08 CST
2.48BMarket Cap-5879P/E (TTM)

BIOCYTOGEN-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(FY)Dec 31, 2020
(FY)Dec 31, 2019
Turnover
34.28%716.91M
42.64%326.84M
50.58%533.88M
--229.13M
39.84%354.56M
49.25%253.54M
--169.87M
Operating income
34.28%716.91M
42.64%326.84M
50.58%533.88M
229.13M
39.84%354.56M
49.25%253.54M
169.87M
Cost of sales
-48.37%-210.88M
-47.15%-91.47M
-32.69%-142.13M
---62.16M
-23.76%-107.12M
-18.99%-86.55M
---72.74M
Operating expenses
-48.37%-210.88M
-47.15%-91.47M
-32.69%-142.13M
-62.16M
-23.76%-107.12M
-18.99%-86.55M
-72.74M
Gross profit
29.17%506.03M
40.96%235.36M
58.32%391.75M
166.97M
48.17%247.44M
71.91%166.99M
97.14M
Selling expenses
-25.04%-62.83M
-21.72%-29.51M
-19.55%-50.25M
---24.24M
-32.78%-42.03M
-8.89%-31.66M
---29.07M
Administrative expenses
-8.67%-286.26M
-9.21%-117.53M
-40.02%-263.41M
---107.63M
23.35%-188.12M
-75.12%-245.42M
---140.14M
Research and development expenses
32.15%-474.37M
24.36%-247.97M
-25.19%-699.17M
---327.82M
-102.13%-558.49M
-74.27%-276.31M
---158.55M
Revaluation surplus
24.37%4.88M
-90.79%942K
-60.02%3.92M
--10.23M
-48.93%9.81M
1,221.48%19.21M
---1.71M
-Changes in the fair value of other assets
24.37%4.88M
-90.79%942K
-60.02%3.92M
--10.23M
-48.93%9.81M
1,221.48%19.21M
---1.71M
Special items of operating profit
-51.26%42.26M
-45.39%20.96M
239.12%86.71M
--38.38M
192.28%25.57M
-21.27%8.75M
--11.11M
Operating profit
49.05%-270.29M
43.57%-137.74M
-4.87%-530.44M
-244.1M
-41.12%-505.82M
-62.02%-358.43M
-221.22M
Financing cost
-77.85%-99.84M
-145.50%-46.66M
-42.39%-56.14M
---19.01M
-74.93%-39.43M
-187.21%-22.54M
---7.85M
Share of profits of associates
32.11%-10.03M
47.46%-4.98M
-3,574.13%-14.77M
---9.48M
-562.07%-402K
--87K
----
Special items of earning before tax
----
----
----
----
----
-23.89%-95.82M
---77.34M
Earning before tax
36.78%-380.16M
30.52%-189.39M
-10.21%-601.35M
-272.59M
-14.46%-545.64M
-55.57%-476.69M
-306.41M
Tax
-247.76%-2.8M
---420K
---804K
----
----
----
----
After-tax profit from continuing operations
36.40%-382.95M
30.37%-189.81M
-10.36%-602.16M
-272.59M
-14.46%-545.64M
-55.57%-476.69M
-306.41M
Earning after tax
36.40%-382.95M
30.37%-189.81M
-10.36%-602.16M
-272.59M
-14.46%-545.64M
-55.57%-476.69M
-306.41M
Minority profit
99.53%-1K
99.52%-1K
-216.42%-212K
---208K
99.86%-67K
-12.59%-48.6M
---43.17M
Profit attributable to shareholders
36.38%-382.95M
30.32%-189.81M
-10.33%-601.95M
-272.39M
-27.44%-545.58M
-62.62%-428.09M
-263.24M
Basic earnings per share
39.24%-0.96
34.25%-0.48
-4.64%-1.58
-0.73
10.12%-1.51
-23.53%-1.68
-1.36
Diluted earnings per share
39.24%-0.96
34.25%-0.48
-4.64%-1.58
-0.73
10.12%-1.51
-23.53%-1.68
-1.36
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Unqualified Opinion
Unqualified Opinion
Auditor
KPMG
--
KPMG
--
KPMG
KPMG
KPMG
(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(FY)Dec 31, 2020(FY)Dec 31, 2019
Turnover 34.28%716.91M42.64%326.84M50.58%533.88M--229.13M39.84%354.56M49.25%253.54M--169.87M
Operating income 34.28%716.91M42.64%326.84M50.58%533.88M229.13M39.84%354.56M49.25%253.54M169.87M
Cost of sales -48.37%-210.88M-47.15%-91.47M-32.69%-142.13M---62.16M-23.76%-107.12M-18.99%-86.55M---72.74M
Operating expenses -48.37%-210.88M-47.15%-91.47M-32.69%-142.13M-62.16M-23.76%-107.12M-18.99%-86.55M-72.74M
Gross profit 29.17%506.03M40.96%235.36M58.32%391.75M166.97M48.17%247.44M71.91%166.99M97.14M
Selling expenses -25.04%-62.83M-21.72%-29.51M-19.55%-50.25M---24.24M-32.78%-42.03M-8.89%-31.66M---29.07M
Administrative expenses -8.67%-286.26M-9.21%-117.53M-40.02%-263.41M---107.63M23.35%-188.12M-75.12%-245.42M---140.14M
Research and development expenses 32.15%-474.37M24.36%-247.97M-25.19%-699.17M---327.82M-102.13%-558.49M-74.27%-276.31M---158.55M
Revaluation surplus 24.37%4.88M-90.79%942K-60.02%3.92M--10.23M-48.93%9.81M1,221.48%19.21M---1.71M
-Changes in the fair value of other assets 24.37%4.88M-90.79%942K-60.02%3.92M--10.23M-48.93%9.81M1,221.48%19.21M---1.71M
Special items of operating profit -51.26%42.26M-45.39%20.96M239.12%86.71M--38.38M192.28%25.57M-21.27%8.75M--11.11M
Operating profit 49.05%-270.29M43.57%-137.74M-4.87%-530.44M-244.1M-41.12%-505.82M-62.02%-358.43M-221.22M
Financing cost -77.85%-99.84M-145.50%-46.66M-42.39%-56.14M---19.01M-74.93%-39.43M-187.21%-22.54M---7.85M
Share of profits of associates 32.11%-10.03M47.46%-4.98M-3,574.13%-14.77M---9.48M-562.07%-402K--87K----
Special items of earning before tax ---------------------23.89%-95.82M---77.34M
Earning before tax 36.78%-380.16M30.52%-189.39M-10.21%-601.35M-272.59M-14.46%-545.64M-55.57%-476.69M-306.41M
Tax -247.76%-2.8M---420K---804K----------------
After-tax profit from continuing operations 36.40%-382.95M30.37%-189.81M-10.36%-602.16M-272.59M-14.46%-545.64M-55.57%-476.69M-306.41M
Earning after tax 36.40%-382.95M30.37%-189.81M-10.36%-602.16M-272.59M-14.46%-545.64M-55.57%-476.69M-306.41M
Minority profit 99.53%-1K99.52%-1K-216.42%-212K---208K99.86%-67K-12.59%-48.6M---43.17M
Profit attributable to shareholders 36.38%-382.95M30.32%-189.81M-10.33%-601.95M-272.39M-27.44%-545.58M-62.62%-428.09M-263.24M
Basic earnings per share 39.24%-0.9634.25%-0.48-4.64%-1.58-0.7310.12%-1.51-23.53%-1.68-1.36
Diluted earnings per share 39.24%-0.9634.25%-0.48-4.64%-1.58-0.7310.12%-1.51-23.53%-1.68-1.36
Currency Unit CNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIAS
Audit Opinions Unqualified Opinion--Unqualified Opinion--Unqualified OpinionUnqualified OpinionUnqualified Opinion
Auditor KPMG--KPMG--KPMGKPMGKPMG

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg